Expert Opinion on Orphan Drugs
metrics 2024
Bridging innovation and care for rare diseases.
Introduction
Expert Opinion on Orphan Drugs is a pivotal academic journal published by Taylor & Francis Ltd, focusing on the burgeoning field of orphan drugs, which are often essential for treating rare diseases. As an integral source of insights and advancements from 2013 to 2024, this journal aims to bridge the gap between emerging scientific research and clinical application, providing a platform for authors to discuss pharmacological innovations and policy implications. With its ISSN 2167-8707, the journal has established a reputably rigorous editorial process and is indexed in Scopus, showcasing its relevance with ranks in various pharmacology and health policy disciplines. Though currently not an open-access journal, it endeavors to deliver high-quality articles that are vital for researchers, healthcare professionals, and policy makers aiming to navigate the complexities and challenges in the orphan drug landscape. It is categorized in Q4 for Health Policy and Q3 for Pharmacology in recent evaluations, reflecting its accessible yet scholarly contributions to this niche area of medical research.
Metrics 2024
Metrics History
Rank 2024
Scopus
IF (Web Of Science)
JCI (Web Of Science)
Quartile History
Similar Journals
NEUROMUSCULAR DISORDERS
Pioneering research for better patient outcomes.NEUROMUSCULAR DISORDERS is a premier academic journal published by PERGAMON-ELSEVIER SCIENCE LTD, focusing on the latest research and developments in the fields of neurology, genetics, and pediatric health. With an ISSN of 0960-8966 and an E-ISSN of 1873-2364, this journal has established a significant presence since its inception in 1991, and it continues to contribute to the scientific community with its impactful findings and reviews. The journal boasts a commendable impact factor, reflected in its placement in the Q2 category for Clinical Genetics and Neurology, as well as its positioning in the top tier Q1 for Pediatrics, Perinatology and Child Health according to the latest quartile assessments. With Scopus rankings such as Rank #71/330 in Pediatrics and Rank #51/99 in Clinical Genetics, NEUROMUSCULAR DISORDERS is recognized for its contribution to advancing knowledge in neuromuscular diseases. The journal is essential for researchers, clinicians, and students interested in the intricate relationship between genetics and neurological disorders, providing valuable insights that drive innovation and improve patient care.
MEDICAL LETTER ON DRUGS AND THERAPEUTICS
Bridging Research and Practice in PharmacologyMEDICAL LETTER ON DRUGS AND THERAPEUTICS is a pivotal resource for professionals in the fields of medicine and pharmacology, published by MED LETTER INC. Since its inception in 1965, this journal has been committed to elucidating the complexities of drug therapy and clinical therapeutics, offering readers evidence-based insights and critical evaluations of the latest medications and treatment protocols. With a quarterly ranking reflecting its stature—Q4 in Medicine (Miscellaneous) and Q3 in both Pharmacology and Pharmacology (Medical)—the journal maintains a specific niche ensuring readers are equipped with updated information that continues to influence healthcare practices. Although it does not operate under an open access model, the journal is accessible to institutions and professionals eager to stay at the forefront of medicinal advancements. The importance of this journal lies in its dedication to enhancing pharmacological knowledge, thus catering to the needs of researchers, healthcare providers, and students alike, making it an essential addition to the literature in therapeutic drug interventions.
Case Reports in Infectious Diseases
Advancing knowledge through unique case insights.Case Reports in Infectious Diseases is a premier open-access journal published by Hindawi Ltd, dedicated to advancing the field of infectious disease research through the dissemination of case reports that highlight unique clinical presentations, innovative treatment approaches, and novel diagnostic techniques. Since its inception in 2011, this journal has provided a vital platform for healthcare professionals, academicians, and researchers to share their findings, thereby enhancing the collective understanding of infectious diseases. Featuring a diverse range of case studies, the journal aims to inspire further research and clinical inquiry, making it an invaluable resource for anyone involved in the fight against infectious diseases. With an easily accessible online format, it caters to a global audience, ensuring that critical insights are available to all stakeholders in this crucial field.
AKTUELLE RHEUMATOLOGIE
Connecting researchers to advance the field of rheumatology.AKTUELLE RHEUMATOLOGIE is a prominent German journal published by GEORG THIEME VERLAG KG, dedicated to advancing the field of rheumatology. Since its inception in 1978, this peer-reviewed journal has been a vital resource for professionals, researchers, and students engaged in the study and treatment of rheumatic diseases. With an ISSN of 0341-051X and an E-ISSN of 1438-9940, the journal provides a platform for sharing groundbreaking research, clinical studies, and reviews. Although classified in the fourth quartile (Q4) of rheumatology journals and ranked 67 out of 73 in its category according to Scopus, AKTUELLE RHEUMATOLOGIE continues to contribute to the discourse in rheumatology. Its comprehensive coverage of recent advancements and innovative approaches makes it an essential publication for anyone interested in the latest developments in the field.
Journal of Rheumatic Diseases
Empowering discovery through open-access rheumatology research.Journal of Rheumatic Diseases, published by the Korean College of Rheumatology, stands as a pivotal platform in the field of rheumatology, contributing significantly to the advancement of knowledge and clinical practice since its inception. With an impact factor reflecting its esteemed position in the academic community, this open-access journal promotes accessibility to high-quality research, ensuring that groundbreaking discoveries are reachable to all stakeholders in the realm of rheumatic diseases. The journal has maintained its commitment to quality, evidenced by its ranking in the Q3 category for Rheumatology in 2023, and its presence among the top quartiles of medical research. Focusing on innovative therapeutic approaches, emerging diagnostic techniques, and comprehensive reviews, the Journal of Rheumatic Diseases seeks to foster collaboration and dialogue among researchers, clinicians, and students alike. For accessibility, the journal offers numerous articles since its transition to open access in 2017, thereby facilitating research dissemination across the globe. As it converges over the years from 2019 to 2024, the journal promises to be instrumental in shaping the future of rheumatic disease research, inviting contributions that inspire new frontiers in this essential field.
Orphanet Journal of Rare Diseases
Uncovering the mysteries of rare diseases.The Orphanet Journal of Rare Diseases, published by BMC since 2006, serves as a vital platform for the dissemination of groundbreaking research in the realm of rare diseases. With a notable Q1 ranking in both the Medicine (miscellaneous) and Pharmacology (medical) categories, and a respectable Q2 ranking in Genetics (clinical), the journal is recognized for its impactful contributions, evidenced by its position in the top quartiles of Scopus rankings. This open-access journal allows unrestricted access to its content, promoting a global exchange of knowledge among researchers, healthcare professionals, and academics. By covering a broad spectrum of rare diseases, the Orphanet Journal aims to enhance awareness, improve diagnosis and treatment, and ultimately contribute to the improvement of patients' lives. With a commitment to high-quality research, this journal stands as an essential resource for anyone involved in the study or treatment of rare diseases.
DRUGS & THERAPY PERSPECTIVES
Navigating the Evolving Landscape of PharmacologyDRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.
JOURNAL OF ENDOCRINOLOGY
Pioneering Research in Endocrine HealthJOURNAL OF ENDOCRINOLOGY, established in 1946 and published by BIOSCIENTIFICA LTD, stands as a premier scholarly outlet in the field of endocrinology, diabetes, and metabolism. With an impressive H-Index reflecting its significant contribution to the literature, this journal maintains a strong presence in academic circles, evidenced by its Q1 ranking in the 2023 Scopus categories for both Endocrinology and Diabetes and Metabolism. With its targeted scope serving a global audience of researchers, professionals, and students, it provides a vital platform for disseminating innovative research findings and advancing the scientific understanding of endocrine systems. As we approach its convergence year of 2024, JOURNAL OF ENDOCRINOLOGY remains committed to publishing high-quality, peer-reviewed articles that explore cutting-edge developments in the field, thereby impacting clinical practices and guiding future research directions.
Journal of Neuromuscular Diseases
Innovating solutions for neuromuscular challenges.Journal of Neuromuscular Diseases, published by IOS PRESS, is a leading platform dedicated to advancing the field of neurology and neuromuscular research. With a focus on delivering high-quality, peer-reviewed content, this journal aims to foster knowledge sharing and collaboration among researchers, clinicians, and healthcare professionals dealing with neuromuscular disorders. The journal boasts a commendable impact factor within its respective categories, achieving Q2 rankings in both Neurology and Clinical Neurology as of 2023. Spanning from its inception in 2014 to the anticipated convergence in 2024, it is recognized for its contributions to critical discussions in the field, evidenced by its rankings of #145 out of 400 in clinical neurology and #75 out of 192 in neuroscience. As an open access journal, it facilitates wider accessibility of research findings, catering to an audience eager for innovative approaches and developments. Set against the backdrop of the vibrant academic scene in the Netherlands, the Journal of Neuromuscular Diseases serves as an essential resource for driving forward the boundaries of knowledge in neuromuscular-related conditions.
CARDIOVASCULAR DRUGS AND THERAPY
Advancing cardiovascular care through cutting-edge research.CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.